Daratumumab monotherapy in heavily pretreated Asians patients with relapsed and refractory multiple myeloma

被引：0
|
作者：
Yoon, Sung-Soo [1 ]
Byun, Ja Min [1 ]
Park, Hyunkyung [2 ]
Lee, Ji Yun [3 ]
Koh, Youngil [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul, South Korea
[2] Seoul Natl Univ, Boramae Med Ctr, Seoul, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Asia; daratumumab; real-world evidence;
D O I：
10.1016/j.clml.2019.09.259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-174
引用
收藏
页码：E155 / E156
页数：2
相关论文
共 50 条
  • [21] ECONOMIC EVALUATION OF DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Salazar, A.
    Guirant Corpi, L.
    Aguirre, A.
    Herrera, M.
    Chacon, C.
    VALUE IN HEALTH, 2018, 21 : S254 - S254
  • [22] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    EJHAEM, 2021, 2 (01): : 56 - 65
  • [23] Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Galusic, Davor
    Krecak, Ivan
    Blaslov, Viktor
    Opara, Andela Krstulovic
    Valkovic, Toni
    Kinda, Sandra Basic
    BIOMEDICINES, 2025, 13 (01)
  • [24] Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
    Alegre, Adrian
    de la Rubia, Javier
    Sureda Balari, Anna
    Encinas Rodriguez, Cristina
    Suarez, Alexia
    Jesus Blanchard, Maria
    Bargay Lleonart, Joan
    Rodriguez-Otero, Paula
    Insunza, Andres
    Palomera, Luis
    Jesus Penarrubia, Maria
    Rios-Tamayo, Rafael
    Casado Montero, Luis Felipe
    Sonia Gonzalez, Marta
    Potamianou, Anna
    Couturier, Catherine
    Pei, Huiling
    Hevia, Henar
    Milionis, Iordanis
    Gaudig, Maren
    Mateos, Maria-Victoria
    HEMASPHERE, 2020, 4 (03):
  • [25] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Blair, Hannah A.
    DRUGS, 2017, 77 (18) : 2013 - 2024
  • [26] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    Drugs, 2017, 77 : 2013 - 2024
  • [27] DARATUMUMAB MONOTHERAPY COMPARED WITH REAL-WORLD HISTORICAL CONTROL DATA IN HEAVILY PRETREATED PATIENTS WITH HIGHLY REFRACTORY MULTIPLE MYELOMA: AN ADJUSTED TREATMENT COMPARISON
    Diels, J.
    Lam, A.
    Ito, T.
    Mehra, M.
    Khan, I.
    HAEMATOLOGICA, 2016, 101 : 521 - 521
  • [28] DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Lakshman, A.
    Abeykoon, J.
    Kumar, S.
    Rajkumar, V.
    Kourelis, T.
    Buadi, F.
    Dingli, D.
    Martha, L.
    Gonsalves, W.
    Dispenzieri, A.
    Kyle, R.
    Lin, Y.
    Go, R.
    Warsame, R.
    Hobbs, M.
    Fonder, A.
    Hwa, Y.
    Hayman, S.
    Russell, S.
    Leung, N.
    Gertz, M.
    Kapoor, P.
    HAEMATOLOGICA, 2017, 102 : 508 - 508
  • [29] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [30] Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
    Oostvogels, Rimke
    Jak, Margot
    Raymakers, Reinier
    Mous, Rogier
    Minnema, Monique C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 60 - 67
12345